Ameriprise
NAGE

Ameriprise’s Niagen Bioscience NAGE Stock Holding History

Ameriprise’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Sell
103,926
-284,352
-73% -$1.54M ﹤0.01% 3621
2025
Q4 		$2.47M Buy
388,278
+4,915
+1% +$34.2K ﹤0.01% 2884
2025
Q3 		$3.58M Buy
383,363
+159,054
+71% +$1.61M ﹤0.01% 2663
2025
Q2 		$3.23M Sell
224,309
-71,844
-24% -$709K ﹤0.01% 2683
2025
Q1 		$2.04M Sell
296,153
-33,835
-10% -$213K ﹤0.01% 2888
2024
Q4 		$1.75M Buy
329,988
+224,399
+213% +$1.23M ﹤0.01% 3000
2024
Q3 		$385K Buy
105,589
+85,499
+426% +$269K ﹤0.01% 3571
2024
Q2 		$54.8K Buy
+20,090
New +$67.2K ﹤0.01% 3812
2023
Q1 		– Sell
-17,517
Closed -$29K – 4045
2022
Q4 		$29K Sell
17,517
-17,867
-50% -$28.3K ﹤0.01% 3884
2022
Q3 		$44K Sell
35,384
-10,300
-23% -$16.6K ﹤0.01% 3897
2022
Q2 		$76K Sell
45,684
-5,015
-10% -$9.81K ﹤0.01% 3808
2022
Q1 		$125K Sell
50,699
-185
-0.4% -$505 ﹤0.01% 3823
2021
Q4 		$190K Sell
50,884
-13,150
-21% -$71K ﹤0.01% 3796
2021
Q3 		$401K Sell
64,034
-385
-0.6% -$3.17K ﹤0.01% 3475
2021
Q2 		$635K Buy
64,419
+36,275
+129% +$316K ﹤0.01% 3374
2021
Q1 		$263K Buy
28,144
+14,160
+101% +$112K ﹤0.01% 3636
2020
Q4 		$67K Hold
13,984
– – ﹤0.01% 3713
2020
Q3 		$56K Hold
13,984
– – ﹤0.01% 3670
2020
Q2 		$64K Sell
13,984
-5
-0% -$22 ﹤0.01% 3609
2020
Q1 		$46K Sell
13,989
-95
-0.7% -$365 ﹤0.01% 3586
2019
Q4 		$61K Hold
14,084
– – ﹤0.01% 3665
2019
Q3 		$55K Hold
14,084
– – ﹤0.01% 3664
2019
Q2 		$65K Buy
+14,084
New +$60.1K ﹤0.01% 3681
2018
Q4 		– Sell
-14,827
Closed -$64K – 3782
2018
Q3 		$64K Buy
14,827
+500
+3% +$2.15K ﹤0.01% 3651
2018
Q2 		$53K Buy
14,327
+2,500
+21% +$9.5K ﹤0.01% 3601
2018
Q1 		$50K Buy
11,827
+275
+2% +$1.44K ﹤0.01% 3586
2017
Q4 		$68K Buy
+11,552
New +$62.4K ﹤0.01% 3585
2017
Q1 		– Sell
-11,755
Closed -$39K – 3691
2016
Q4 		$39K Buy
+11,755
New +$31.9K ﹤0.01% 3813

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise's NAGE Position: Q1 2026 in Review

Ameriprise reduced its Niagen Bioscience (NAGE) stake by 73% in Q1 2026, selling an estimated $1.54M and leaving 103,926 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Ameriprise first reported a position in NAGE in Q4 2016 and has held it in 28 quarters since. The position peaked at $3.58M in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Ameriprise held 103,926 shares of Niagen Bioscience worth $458K as of Q1 2026.
  • Ameriprise sold 284,352 Niagen Bioscience shares in Q1 2026, an estimated $1.54M.
  • Niagen Bioscience made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3621 holding.
  • Ameriprise first reported a position in Niagen Bioscience in Q4 2016 and has held it in 28 quarters since.
  • Ameriprise's Niagen Bioscience position peaked at $3.58M in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.